From Conference Call Transcript: "
Moving forward, we expect growing profitability for the remainder of 2014 based primarily on escalation of revenues. Despite nearly doubling our sales over first quarter of 2013, which is generally, the first quarter is generally a slower sales quarter based on finalizing budgets in receiving new annual assets, first quarter of 2014 revenues would have been higher based on two important factors. The first one is that Allscripts had a privacy and technical issue that affected their distribution of eCoupons and other programs during a significant period of time it took to fully resolved the issue. The second is one of our largest clients interrupted their program to determine promotional impact and return on investment of that particular program. Both of the above have been resolved. Allscripts has resolved technical and privacy issues. It is now beginning to roll out activation of SampleMD's eCoupon automation unless providers opt out. We anticipate this to have a significant impact on June sales and beyond once this is completed by increasing our reach to another 20,000 physicians."
OPRX issued 8.3M shares at $1.20. Proceeds were $9M after fees, of which $6M was used to buyout the Vicis position. The end result is that the fully diluted share count falls from 34.1M to 26.7M, of which there are only 23.5M outstanding (3.2M in options/warrants). So the market cap is roughly $40M, plus they now have nearly $4M cash.